Examination of the clinical remission and functional remission in Infliximab using the increase-in-quantity protocol to TNF-alpha inhibitory drug resistance rheumatoid arthritis

Examination of the clinical remission and functional remission in Infliximab using the increase-in-quantity protocol to TNF-alpha inhibitory drug resistance rheumatoid arthritis - Examination of the clinical remission and functional remission in Infliximab using an increase-in-quantity protocol

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014311

Enrollment

Registered

2014-06-24

Start date

2014-06-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rheumatoid arthritis

Interventions

The quantity of Infliximab is increased.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)The patient under medical treatment with TNF-alpha inhibitory drugs other than Infliximab 2)age 20 years and over, age 75 years old and below 3)Man and woman

Exclusion criteria

Exclusion criteria: 1)The patient who cannot use MTX 2)The patient who cannot use Infliximab 3)THe patient who ever used Infliximab

Design outcomes

Primary

Measure	Time frame
clinical remission and functional remission	—

Countries

Japan

Contacts

Public ContactJun Kishi

Institute of Health Biosciences, Department of Respiratory Medicine and Rheumatology

kishijun@clin.med.tokushima-u.ac.jp088-633-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026